Body Composition Changes After Bariatric Surgery or GLP-1RA
Delivered as a cyclical, nonFDA-approved protocol with informed consent, the program layers nightly or nearnightly injections, labs (including IGF1), and a tailored training and nutrition plan
Degraded peptide may not suppress cravings as effectively, leading to a return of the food noise that tirzepatide normally quiets
The advantages include integrated, face-to-face care and established patient relationships
Tracking your progress and adjusting your approach Managing GLP-1 constipation is not a one-size-fits-all proposition
Transitioning from weight loss to maintenance Determining goal weight achievement: Lost 10-12% body weight (cagrilintide alone) Lost 15-25% body weight (CagriSema) Weight stable for 4-8 weeks Satisfied with current weight Ready to focus on maintenance Maintenance dose options comparison: Option 1: Continue same dose Keep cagrilintide at 2.4mg weekly Ensures no regain Most conservative approach Highest cost Option 2: Reduce dose slightly Decrease to 1.8-2.0mg weekly Monitor weight for 4 weeks If stable, maintain If gaining, increase back 20-25% cost savings Option 3: Try every 10 days Instead of weekly, inject every 10 days Effectively 30% dose reduction Some maintain weight this way Requires close monitoring Recommendation: Try Option 2 first (reduce to 1.8-2.0mg)